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Like any organ, the brain is susceptible to the march of time and a reduction in mitochondrial biogenesis
is a hallmark of the aging process. In the largest investigation of mitochondrial copy number in Par-
kinson’s disease (PD) to date and by using multiple tissues, we demonstrate that reduced Parkinson DNA
(mitochondrial DNA mtDNA) copy number is a biomarker for the etiology of PD. We used established
methods of mtDNA quantiﬁcation to assess the copy number of mtDNA in n ¼ 363 peripheral blood
samples, n ¼ 151 substantia nigra pars compacta tissue samples and n ¼ 120 frontal cortex tissue
samples from community-based PD cases fulﬁlling UK-PD Society brain bank criteria for the diagnosis of
PD. Accepting technical limitations, our data show that PD patients suffer a signiﬁcant reduction in
mtDNA copy number in both peripheral blood and the vulnerable substantia nigra pars compacta when
compared to matched controls. Our study indicates that reduced mtDNA copy number is restricted to the
affected brain tissue, but is also reﬂected in the peripheral blood, suggesting that mtDNA copy number
may be a viable diagnostic predictor of PD.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction cannot fully explain the gross neuronal loss seen in PD. Conversely,Parkinson’s disease (PD) is a prototypical age-related neurode-
generative disease, affecting approximately 1% of the worldwide
elderly population. The etiopathogenesis of PD is complex and
multifactorial, including contributions from environmental and
genetic factors, with aging remaining the strongest risk factor.
Sporadic PDwas ﬁrst linked tomitochondrial function in the late
1970’s, when the potent respiratory chain inhibitor 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine was shown to cause parkin-
sonism in illicit drug users (Davis et al., 1979). Subsequent studies,
focusing on complex I-mediated reactive oxygen species formation
link PD to a vicious circle of oxidative stress and bioenergetic fail-
ure. Moreover, there is compelling evidence that mitochondrial
quality control and stress responses are affected by PD-associated
genes (Hatano et al., 2004; Mills et al., 2008; Mullin and Schapira,
2013). At the cellular genetic level, reports have indicated that
mitochondrial DNA (mtDNA) deletion formation may contribute to
etiology (Reeve et al., 2013); however, these isolated ﬁndingsGroup, Institute of Genetic
castle upon Tyne, NE1 3BZ,
6.
n).
Inc. This is an open access articlecomprehensive population studies, focusing on the role of inherited
mtDNA variants, have identiﬁed phylogenetic clades which repro-
ducibly affect PD risk (Ghezzi et al., 2005; Hudson et al., 2013, 2014;
Latsoudis et al., 2008).
The increase of mitochondrial biogenesis, hallmarked by a char-
acteristic increase in cellularmtDNA level (Giordano et al., 2014), is a
typical compensatory response to gross mitochondrial dysfunction
(Lee et al., 2000) and has been reported in mitochondrial disorders
characterized by a complex I defect (Giordano et al., 2014).
Here, we studied themtDNA content in multiple tissues from PD
patients and matched control subjects, comparing mtDNA copy
number to cardinal measurements of PD etiology. Our observations
indicate that mitochondrial biogenesis, meditated through mtDNA
copy number, is important in the development of PD. In addition,
our data suggest that mtDNA copy number may be a viable diag-
nostic predictor of PD.
2. Materials and methods
2.1. Patient cohort
We studied the role of mtDNA copy number in n ¼ 363 pe-
ripheral blood samples, n ¼ 151 substantia nigra pars compacta
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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from community-based PD cases fulﬁlling UK-PD Society brain
bank criteria for the diagnosis of PD (Hughes et al., 1992),
comparing the results to matched control samples with no clinical
evidence of PD (n ¼ 262 peripheral blood samples, n ¼ 33 SNpc
tissue samples, and n ¼ 37 frontal cortex tissue samples). All were
of Caucasian origin. All blood samples underwent cognitive
assessment, including global cognitive function was assessed using
the mini-mental state examination (MMSE) (Roth et al., 1986) and
the Montreal Cognitive Assessment (Nasreddine et al., 2005).
Cognitive impairment was determined using published criteria
(using 1.5 standard deviation as a cutoff) (Yarnall et al., 2014). In
addition, samples were genotyped for variants known to affective
cognitive function: rs9468 (deﬁning H1/H2, MAPT) and rs429358/
rs7142 (deﬁning APOE1-4).(Nombela et al., 2014) Genotyping was
performed by KASP genotyping (LGC, Middlesex, UK).2.2. MtDNA copy number determination
Total DNA was extracted from blood and tissue samples using
standard methods. Quantiﬁcation of mtDNA was performed in
triplicate by multiplex Taqman qPCR ampliﬁcation of the mito-
chondrial genes MTND1 and MTND4 and the nuclear encoded gene
B2M, using serial dilutions of cloned vectors to ensure reaction
linearity and for standard curve quantiﬁcation, as previously
detailed (Grady et al., 2014). MtDNA copy number is expressed as a
relative abundance of both MTND1 and MTND4 to the nuclear
counterpart, with a correlation of r2 ¼ 0.9941 (MTND1:MTND4
derived copy number). This method was preferred to absolute (or
standard curve) approaches as the low amount of DNA from
microdissected tissues does not allow appropriate standard curve
preparation (Giordano et al., 2014). Patient and control samples
were randomly assigned to each run to limit run-speciﬁc
stratiﬁcation.2.3. Validation of qPCR results
A random proportion (10%) of samples was replicated from
source DNA, with a coefﬁcient or repeat variance estimated as 0.3%
(indicating that qPCR results are reproducible).2.4. Statistical analysis
Data were analyzed using SPSS v22 with data-appropriate tests
(detailed in text). Statistical signiﬁcance was set at p  0.05.Fig. 1. Analysis of mitochondrial DNA (mtDNA) content in 3 tissues, showing mean mtDN
(C, unshaded) from (A) peripheral blood cells (PBC), (B) substantia nigra pars compacta (SNp
***p ¼ 103). Abbreviation: PD, Parkinson’s disease.2.5. Ethics
Local study approval was granted (NRES Committee North East-
Newcastle & North Tyneside 1).
3. Results
We initially investigated the role of mtDNA copy number in
peripheral white blood cells (PBCs), identifying a signiﬁcant
reduction in mtDNA copy number in PD cases when compared to
controls (case mean ¼ 163  89, control mean ¼ 195  129, Mann-
Whitney p¼ 2.86 104, Fig.1A). This associationwas independent
of age (linear regression PD vs. controls with age as a covariate, p ¼
3.0  104) and gender (males only, A ¼ 227 vs. U ¼ 129, Mann-
Whitney p ¼ 5.3  104 and females only, A ¼ 133 vs. U ¼ 132,
Mann-Whitney p ¼ 4.8  102).
Stratiﬁcation to affected individuals only failed to ﬁnd a signif-
icant association between PBC mtDNA copy number and pheno-
typic assessments, including dementia (Mann-Whitney p ¼ 6.7 
101), cognitive impairment (Mann-Whitney p ¼ 3.9  101),
MMSE score (Spearman correlation p ¼ 6.85  101), Montreal
Cognitive Assessment score (Spearman correlation p¼ 1.79 101),
power of attention (Spearman correlation p ¼ 8.27  101), conti-
nuity of attention (Spearman correlation p ¼ 6.90  101), and
cognitive reaction time (Spearman correlation p ¼ 4.96  101;
Table 1). Interestingly, we were able to identify a signiﬁcant asso-
ciation between reduced PBC mtDNA copy number and smoking
history (deﬁned as current smoker or smoked <5 y from disease
onset) in PD cases (Mann-Whitney p ¼ 4.0  103, Table 1); how-
ever, we found no direct link between smoking history and PD
(case/control p ¼ 2.9  101).
Subsequent analysis of isolated brain tissue revealed a similar
reduction ofmtDNA copy number in PD cases, statistically signiﬁcant
in the vulnerable SNpc (Mann-Whitney U p ¼ 4.0  103, Fig. 1B),
but not in the asymptomatic FC (Mann-Whitney U p ¼ 2.91  101,
Fig.1C). Substratiﬁcation by gender revealed a signiﬁcant association
between SNpcmtDNA copy number inmales (males only, A¼ 100 vs.
U¼ 25,Mann-Whitney p¼ 5.0104), but not in females (A¼ 49 vs.
U ¼ 8, Mann-Whitney p ¼ 3.97  101); likely a result of low female
sample numbers.We found no signiﬁcant gender effect in FCmtDNA
copy number. Correcting for age, as a covariate in linear regression,
supported the association in SNpc (p¼ 4.5103) and did not affect
the result in FC (p¼ 8.4102). In addition, we found no association
between SNpc or FC tissue mtDNA copy number and dementia,
MMSE, cognitive impairment, or smoking (Table 1). However, again,
this is likely a direct result of a smaller sample number.A copy number per cell (with 95% CI) for PD cases (A, shaded) and matched controls
c), and (C) frontal cortex (FC). Asterisks indicate statistical signiﬁcance (****p ¼ 104 and
Table 1
Analysis of mtDNA copy number to key PD-related phenotypes, smoking history, and
mtDNA haplogroup in PD cases
Samples Tissue
Blood SNpc FC
n ¼ 363 n ¼ 151 n ¼ 120
mtDNA copy number versus
Dementia* 6.87  10-1 4.70  10-1 3.48  10-1
Cognitive impairment* 3.91  10-1 5.32  10-1 6.54  10-1
MMSE** 6.85  10-1 6.15  10-1 1.65  10-1
MoCA** 1.79  10-1 d d
Power of attention** 8.27  10-1 d d
Continuity of attention** 6.90  10-1 d d
Cognitive reaction time** 4.96  10-1 d d
Smoking* 4.10  10-3 7.29  10-1 9.87  10-1
mtDNA haplogroup*** 6.87  10-1 6.02  10-1 8.45  10-1
* Testing by Mann-Whitney U of mtDNA copy number versus binary variable,
** Testing by Spearman correlation of mtDNA copy number versus linear variable,
and *** ANOVA testing of mtDNA copy number versus categorical variable.
Key: ANOVA, analysis of variance; FC, frontal cortex; MoCA, Montreal Cognitive
Assessment; MMSE, mini-mental state examination; mtDNA, mitochondrial DNA;
PD, Parkinson’s disease; SNpc, substantia nigra pars compacta.
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mtDNA copy number, mediated through respiratory chain coupling
and reactive oxygen species,(Gomez-Duran et al., 2012; Liou et al.,
2010) we found no link between mtDNA copy number and
mtDNA haplogroup afﬁliation in PBC, SNpc, or FC tissue, when
analyzed as separately or combined (cases þ control; Table 1).
4. Discussion
In the largest study in PD to date, our observations indicate that
mtDNA copy number is an important component in the pathoeti-
ology of PD. Using different tissues, we have demonstrated that in
high-turnover tissues such as PBCs and in vulnerable postmortem
tissues such as the SNpc, mtDNA copy number is reduced and may
be an important early biomarker for PD onset. Our results are in-
keeping with similar reductions in mtDNA copy number reported
in a number of other age-related neurological disorders where
mitochondrial dysfunction was also a hallmark; For example, a PBC
copy-number reduction in Huntington’s disease (Petersen et al.,
2014) and a reduction of mtDNA in pyramidal neurons in
Alzheimer’s disease hippocampi (Rice et al., 2014).
Interestingly, we found no link between cognitive phenotypes
and mtDNA copy number, but our data indicate that smoking may
be a factor in the reduction of mtDNA copy number in PD cases,
supported by previous reports that cigarette smoke is linked to a
reduction in PBC mtDNA (Xie et al., 2013). We also ﬁnd no link
betweenmtDNA an age of onset; however, this is likely a product of
a limited age range of our samples (mean agedPBC ¼ 69.1 StDev ¼
8.8, SNpc ¼ 76.0 StDev ¼ 8.5, and FC ¼ 76.1 StDev ¼ 10.0) and the
fact that mitochondrial dysfunction in PD occurs during the early
stages of neurodegeneration (Morais and De Strooper, 2010).
What limitations can we identify?We cannot rule out the effect of
pharmacokinetics. A reduction in hippocampal and PBC mtDNA
copy number was reported in chronic opiate abusers, mediated
through autophagy (Feng et al., 2013). The complex and multifac-
eted nature of PD drug treatmentmakes these observations difﬁcult
to test and would require signiﬁcantly larger sample numbers. Most
of our observations are made in mtDNA isolated from peripheral
blood, where differential blood composition (i.e., varying leukocyte
count) could stochastically confound our results. However, as cell
population of blood is highly regulated and we report mtDNA copy
number corrected by cell number (using a housekeeping gene), we
believe this is not an issue. In addition, we cannot completelycontrol for is cell loss. Postmortem assessment of neuronal cell
death will be anecdotal at best, and although studying isolated
postmortem SNpc, we cannot completely rule out glial contami-
nation in PD cases, where a loss of most neurons has occurred.
However, glial contamination alone could not explain the gross
mtDNA copy-number differences seen between cases and age-
matched controls in the SNpc, moreover in the effect in PBCs.
Measuring mtDNA content in cells and tissues is not without
problem. Extraction techniques affect template availability and can
affect downstream processes, with varying mtDNA sequence
affecting speciﬁcity. We mitigated these issues, using an estab-
lished, internally correcting triplex probe-based approach (Grady
et al., 2014); however, it is important that this effect is replicated
in a similar cohort of PD patients and potentially expanded to a
range of neurodegenerative diseases.
Finally, our observations are based on a single experimental
series and, although our PBC and SNpc data are complimentary, we
cannot wholly determine if this phenomenon is cause or effect or
indeed limited to the brain regions under study. To address this
further, we recommend longitudinal studies in PD patients, pref-
erably investigating further vulnerable (i.e., cingulate) and unaf-
fected brain regions.
5. Conclusion
Accepting our limitations, our study indicates that reduced
mtDNA copy number in PBCs, supported by a subsequent reduction
in the affected brain region, is a viable biomarker for the detection
of PD.
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